To include your compound in the COVID-19 Resource Center, submit it here.

Oxygent perflubron: Began Phase III study

Alliance Pharmaceutical Corp. (ALLP), San Diego, Calif.
Product: Oxygent perflubron
Business: Blood products/substitutes
Therapeutic category: Blood substitute
Target: N/A
Description: Intravenous

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE